Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 30, 2030

Study Completion Date

December 30, 2032

Conditions
Orodental Injury
Interventions
BEHAVIORAL

Radiotherapy followed by chemotherapy

"Researchers would like to test the accuracy of the MRI data being used for this study. If you agree, you will have 2 additional MRI scans within 2 weeks before Visit 1.~The first 90 participants who agree will be selected to have the following scans:~* 35 participants will be scanned 2 times on one MRI device (Device #1).~* 35 participants will be scanned 2 times on another MRI device (Device #2).~* 20 participants will be scanned 1 time on both MRI devices (Device #1 and #2). If you agree and you are chosen, the study doctor will tell you if you will have scans on~ 1. or 2 MRI devices."

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT06586892 - Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | Biotech Hunter | Biotech Hunter